We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+9.7%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$300M
Cap. Flow
+$374M
Cap. Flow %
23.51%
Top 10 Hldgs %
49.78%
Holding
111
New
24
Increased
22
Reduced
23
Closed
30

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$67.1M
2
NVCR icon
NovoCure
NVCR
+$58M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$38.1M
4
AZN icon
AstraZeneca
AZN
+$28.6M
5
IART icon
Integra LifeSciences
IART
+$27.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$35.3M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$33.2M
3
RVMD icon
Revolution Medicines
RVMD
+$25.4M
4
TXG icon
10x Genomics
TXG
+$21.5M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 83.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
76
GSK
GSK
$105B
$342K 0.02%
10,110
-27,390
-73% -$986K
WGS icon
77
GeneDx Holdings
WGS
$2.2B
$307K 0.02%
+4,000
New +$279K
THC icon
78
Tenet Healthcare
THC
$20.7B
$256K 0.02%
+2,027
New +$301K
ONC
79
BeOne Medicines Ltd
ONC
$38.5B
$212K 0.01%
1,150
-81,600
-99% -$16.7M
ELV icon
80
Elevance Health
ELV
$84.5B
$203K 0.01%
550
-29,100
-98% -$12.2M
IOBT
81
DELISTED
IO Biotech
IOBT
$177K 0.01%
192,670
– –
ABBV icon
82
AbbVie
ABBV
$431B
– –
-15,750
Closed -$3.11M
ALEC icon
83
Alector
ALEC
$210M
– –
-1,207,371
Closed -$5.63M
APLT
84
DELISTED
Applied Therapeutics
APLT
– –
-680,784
Closed -$5.79M
ARVN icon
85
Arvinas
ARVN
$572M
– –
-228,800
Closed -$5.64M
BCAB icon
86
BioAtla
BCAB
$5.43M
– –
-50,350
Closed -$4.43M
BCYC
87
Bicycle Therapeutics
BCYC
$284M
– –
-78,315
Closed -$1.77M
BDSX icon
88
Biodesix
BDSX
$237M
– –
-201,903
Closed -$7.19M
BHC icon
89
Bausch Health
BHC
$2.21B
– –
-1,424,000
Closed -$11.6M
CRVO icon
90
CervoMed
CRVO
$26.3M
– –
-126,614
Closed -$1.85M
DYN icon
91
Dyne Therapeutics
DYN
$4.83B
– –
-117,500
Closed -$4.22M
ENGN icon
92
enGene Therapeutics
ENGN
$121M
– –
-800,000
Closed -$5.28M
ENTA icon
93
Enanta Pharmaceuticals
ENTA
$391M
– –
-785,546
Closed -$8.14M
IDYA icon
94
IDEAYA Biosciences
IDYA
$3.52B
– –
-1,049,314
Closed -$33.2M
IMVT icon
95
Immunovant
IMVT
$8.14B
– –
-9,678
Closed -$276K
KIDS icon
96
OrthoPediatrics
KIDS
$595M
– –
-288,945
Closed -$7.83M
KNSA icon
97
Kiniksa Pharmaceuticals
KNSA
$6.07B
– –
-302,500
Closed -$7.56M
KROS icon
98
Keros Therapeutics
KROS
$211M
– –
-224,600
Closed -$13M
NTRA icon
99
Natera
NTRA
$44.9B
– –
-29,900
Closed -$3.8M
OLMA icon
100
Olema Pharmaceuticals
OLMA
$1.04B
– –
-103,500
Closed -$1.24M
1 2 3
4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Soleus Capital Management held 111 positions worth $1.59B, up 23% from $1.29B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management deployed $374M of net new capital in Q4 2024, opening 24 new positions and adding to 22 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 1,001,400 shares worth $65.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 93% a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $25.4M trimmed.

  • Soleus Capital Management's largest Q4 2024 buy was BioMarin Pharmaceuticals: 1,001,400 shares worth $65.8M.
  • Soleus Capital Management added most to Krystal Biotech in Q4 2024, an estimated $25.1M increase.
  • Soleus Capital Management's biggest Q4 2024 reduction was Revolution Medicines, cutting an estimated $25.4M.
  • Soleus Capital Management fully exited Sanofi in Q4 2024, selling an estimated $35.3M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $1.59B portfolio in Q4 2024.
  • Soleus Capital Management opened 24 new positions and closed 30 in Q4 2024.
  • Soleus Capital Management's portfolio value rose 23% quarter-over-quarter to $1.59B.

Based on Soleus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.